Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM-101 Phase I in Healthy Volunteers
NCT05790382Phase 1Unknown
- Sponsor
- Neuramedy
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing NM-101 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Related Adverse Events by Severity up to 4 months and Pharmacokinetic Parameters up to 4 months. Status: unknown.
02
Drugs
tomaralimab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05790382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790382.